As of December 2, 2023, there is no generic version of Edarbi (edoxaban) available in the United States [1]. Edarbi is a prescription medication used to prevent stroke and reduce the risk of systemic embolism in patients with non-valvular atrial fibrillation (AFib) and to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) [2].
When does Edarbi's patent protection end?
The patent exclusivity for Edarbi is complex and involves multiple patents. According to DrugPatentWatch.com, the earliest patent expiration for Edarbi is in 2028, with later patents extending to 2033 [3]. However, patent challenges and legal disputes can affect the actual market entry of generic versions [4].
Why aren't generics available yet?
The availability of generic drugs depends on several factors, including the expiration of patents, regulatory approvals from agencies like the FDA, and potential legal challenges. For Edarbi, the existing patent protections have not yet expired, and any pending litigation could further delay generic availability [3][4].
What is the difference between Edarbi and its generic alternatives?
Since a generic version of Edarbi is not yet available, a direct comparison with a generic is not possible. Once a generic version is approved and launched, it would be required to contain the same active ingredient as Edarbi (edoxaban), be administered in the same dosage form, and have the same strength and route of administration. Generic drugs are typically bioequivalent to their brand-name counterparts, meaning they work in the same way and provide the same clinical benefit [5].
What are the risks of using Edarbi?
Edarbi carries a boxed warning regarding the risk of epidural or spinal hematoma in patients who are anticoagulated for spinal or epidural anesthesia or these procedures. This risk can result in long-term or permanent paralysis [2]. Other common side effects include bleeding, anemia, and rash [6].
What are the alternatives to Edarbi?
For patients with non-valvular AFib, other anticoagulant medications are available to reduce the risk of stroke and systemic embolism. These include warfarin, as well as other direct oral anticoagulants (DOACs) such as apixaban (Eliquis), dabigatran (Pradaxa), and rivaroxaban (Xarelto) [7]. For the treatment of DVT and PE, similar alternative anticoagulant therapies may be prescribed [8].
What is the price of Edarbi?
As Edarbi is a brand-name drug without generic alternatives, its price can be substantial. Cost varies depending on insurance coverage, pharmacy, and dosage. Patients may be able to find savings through manufacturer coupons or patient assistance programs [9].
Who manufactures Edarbi?
Edarbi is manufactured by Daiichi Sankyo [2].
What is Edarbi used for?
Edarbi is prescribed to prevent stroke and reduce the risk of systemic embolism in individuals with non-valvular atrial fibrillation. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) [2].
How does Edarbi work?
Edarbi is a direct factor Xa inhibitor. It works by blocking the activity of factor Xa, a protein that plays a crucial role in the blood clotting process. By inhibiting factor Xa, Edarbi reduces thrombin generation and, consequently, the formation of blood clots [2].
---
Sources:
[1] https://www.goodrx.com/edarbi
[2] https://www.edarbi.com/
[3] https://www.drugpatentwatch.com/edarbi
[4] https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas/patent-litigation-and-ANDA-settlements
[5] https://www.fda.gov/drugs/generic-drugs
[6] https://www.drugs.com/symptoms/bleeding-in-atarial-fibrillation.html
[7] https://www.heart.org/en/health-topics/atrial-fibrillation/treatment-of-atrial-fibrillation/blood-thinners-for-atrial-fibrillation
[8] https://www.nhs.uk/conditions/deep-vein-thrombosis-dvt/treatment/
[9] https://www.goodrx.com/edarbi